Should I take statins if I have (not yet) had a heart problem?
Whether statins are worthwhile depends on your personal risk. At a calculated 10-year risk of 10% or higher and at least one risk factor, such as high blood pressure, diabetes or smoking, major guidelines recommend statins for people aged 40 to 75.
Statins can protect you against a first heart attack or stroke, even if you have never had one. But whether that makes sense for you personally depends strongly on your individual risk. A meta-analysis of 22 trials involving more than 90,000 participants shows that, in people with elevated risk, statins reduce the chance of a heart attack by around 33% and the chance of a stroke by around 22%. In absolute terms: for every 100 people who take them for 2.5 years, a serious cardiovascular event is prevented in an average of one person. Modest, then, but at a high personal risk that difference can still be significant.1
Not everyone benefits equally. For people aged 50 to 75, a separate meta-analysis found no evidence that statins reduce overall mortality; only one of the eight studies examined demonstrated that.2 The US Preventive Services Task Force recommends statins for people aged 40 to 75 with at least one risk factor (high blood pressure, elevated cholesterol, smoking or diabetes) and a calculated 10-year risk of 10% or higher. If you fall between 7.5 and 10%, that decision is made together with your doctor. Above age 76 without existing heart disease, there is simply too little evidence to make a recommendation.3
Side effects deserve an honest conversation. Muscle pain complaints occur somewhat more often, but clinically confirmed muscle disorders were not found significantly more frequently. Mild liver function problems have also been described. The risk of type 2 diabetes is not significantly increased overall, although one study did find a 25% higher risk with high-intensity statins. According to the largest meta-analysis, the side effects do not outweigh the protective effects.4
People with type 1 diabetes without prior heart disease appear to benefit clearly. In a study involving more than 20,000 people, statin use was associated with 1.66 to 3.48 percentage points less mortality and 1.63 to 2.69 percentage points fewer cardiovascular events over ten years. The effect was greater in women, in people aged 40 and older, and at higher cholesterol levels. Because this is an observational study, causality cannot be established, but the outcomes are consistent with what randomised trials show.5
There are also critical scientific voices. A group of researchers argues that statin studies use relative rather than absolute figures to make their benefits appear larger, and that the causal evidence for cholesterol as the culprit is weaker than is often presented. This is a minority position that most cardiologists dispute, but it does underline that the absolute effects are modest.6,7
The core of the evidence consists of three meta-analyses (PMID 35997724, 33196766, 34261627) with tens of thousands of participants combined. The USPSTF guideline (PMID 35997723) provides the practical framework. A large observational study in type 1 diabetes adds to this (PMID 40930617). Two critical opinion pieces have been included as a minority position (PMID 30198808, 25672965). In total, the randomised evidence base covers approximately 150,000+ unique participants, with participant numbers partially overlapping between meta-analyses.